ipilimumab,nivolumab
bms
['cm 214', 'rcc,(-irccs),(-srcc),(-urcc)']
association between hrqol and clinical outcomes in cm 214. baseline hrqol scores are a potential predictor for survival in arcc, and hrqol changes are informative for pts expected survival #asco22 
Medical oncologist. Clinical researcher focused in GU tumors. Director Institute of Oncology. Associate Professor UCM. Hospital Clinico San Carlos Madrid, Spain